<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972982</url>
  </required_header>
  <id_info>
    <org_study_id>2018YFC1314102</org_study_id>
    <nct_id>NCT03972982</nct_id>
  </id_info>
  <brief_title>Effects of Structured Simplified Short-term Intensive Insulin Therapy on Long-term Glycemic Remission</brief_title>
  <official_title>Induction of Long-term Glycemic Remission Via Structured Simplified Short-term Intensive Insulin Therapy in Patients With Newly Diagnosed Type 2 Diabetes: a Multiple Centered, Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Short-term intensive insulin therapy is shown to induced glycemic remission, but&#xD;
      traditionally patients were hospitalized for 2-4 weeks in order to receive the therapy, the&#xD;
      long inpatient period precluded the wide application of the thrapy. This study aims to&#xD;
      invesitgate whether simplified regimen is non-inferior to traditional regimen in achieving&#xD;
      long-term glycemic remisson.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission rate</measure>
    <time_frame>24 weeks after withdrawal of the medical intervention</time_frame>
    <description>Remission is defined as fasting plasma glucose less than 7mmol/L and GHbA1c less than 7% without any hypoglycemic agents</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Newly Diagnosed Type 2 Diabetes</condition>
  <condition>Simplified Short-term Intensive Insulin Therapy</condition>
  <condition>Glycemic Remission</condition>
  <arm_group>
    <arm_group_label>Simplified regimen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week，Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inpaitent short-term continuous subcutaneous insulin infusion will be administered to maintained euglycemia for 2 weeks, Then subjects will be follow-up routinely.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simplified intensive insulin therapy regimen</intervention_name>
    <description>Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.</description>
    <arm_group_label>Simplified regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traditional Short-term Intensive insulin therapy</intervention_name>
    <description>Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up</description>
    <arm_group_label>Routine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly diagnosed type 2 diabetes with no prior hypoglycemic agents application, or on&#xD;
             hyperglycemic monotherapy for less than 1 week;&#xD;
&#xD;
          -  GHbA1c ≥ 9%&#xD;
&#xD;
          -  Body mass index between 20-35kg/m2&#xD;
&#xD;
          -  Capable to use wearable devices and mobile Apps;&#xD;
&#xD;
          -  willling to follow the study protocol and data collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes or specific types of diabetes;&#xD;
&#xD;
          -  Allergic or intolercance to medicine used in the study;&#xD;
&#xD;
          -  Acute diabetic complications (diabetic ketoacidosis, hyperosmotic hyperglycemia coma&#xD;
             or lactic acidosis);&#xD;
&#xD;
          -  Severe diabetic microvascular complications (proliferative retinopathy, clinical&#xD;
             proteinuria,uncontrolled diabetic neuropathy and obvious diabetic autonomic&#xD;
             neuropathy;&#xD;
&#xD;
          -  Glomerular filtration rate less than 50 ml/min&#xD;
&#xD;
          -  ALT &gt;2.5 times of the upper limit of normal (ULN), or bilirubin &gt; 1.5 times of ULN；&#xD;
&#xD;
          -  Significant Macrovascular disease:acute cerebrovascular accident, acute coronary&#xD;
             syndrome or peripheral artery disease that required vascular intervention or&#xD;
             amputation 12 months before enrollment;&#xD;
&#xD;
          -  Poor blood pressure control (systolic blood pressure≥180mmHg and/or sitting diastolic&#xD;
             blood pressure ≥110mmHg) and unable to control under 160/110mmhg within 1 week;&#xD;
&#xD;
          -  Hemoglubin level &lt; 100g/L or required regular blood transfusion;&#xD;
&#xD;
          -  Chronic cardiac dysfunction with NYHA grade III or above;&#xD;
&#xD;
          -  Use of medicines that affect blood glucose for a cumulative time of more than 1 week&#xD;
             within the prior 12 weeks, such as oral/venous glucocorticoid, growth hormone,&#xD;
             estrogen/ progesterone, high-dose diuretics, antipsychotic drugs. However, low-dose&#xD;
             diuretics for antihypertensive purposes (HCTZ &lt; 25mg/d, indapamide &lt; 1.5mg/d) and&#xD;
             physiologic replacement of thyroid hormone are allowed;&#xD;
&#xD;
          -  Serious systemic disease or malignant tumor, chronic diarrhea, etc；&#xD;
&#xD;
          -  Uncontrolled abnormalty in endocrine glands (Cushing's syndrome, hyperthyroidism,&#xD;
             etc.);&#xD;
&#xD;
          -  Any factors that may affect the participation of the subject in the study or the&#xD;
             evaluation of the results；&#xD;
&#xD;
          -  Pregnancy or planned pregnancy, lactation subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>endocrinology department of the first affiliated hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 1, 2019</study_first_submitted>
  <study_first_submitted_qc>June 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 1, 2019</last_update_submitted>
  <last_update_submitted_qc>June 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanbing Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

